<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1036">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571697</url>
  </required_header>
  <id_info>
    <org_study_id>CR108890</org_study_id>
    <secondary_id>PCSNSP002938</secondary_id>
    <nct_id>NCT04571697</nct_id>
  </id_info>
  <brief_title>A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy</brief_title>
  <official_title>Comparing Rates of Dementia and Alzheimer's Disease in Patients Initiating Methotrexate Versus Those Initiating Anti-TNF-Î± Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the risk of dementia in participants diagnosed with&#xD;
      rheumatoid arthritis (RA) exposed to anti-tumor necrosis factor (TNF) therapy versus those&#xD;
      exposed to methotrexate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Actual">October 27, 2020</completion_date>
  <primary_completion_date type="Actual">October 27, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Newly Diagnosed Dementia Cases</measure>
    <time_frame>365 days</time_frame>
    <description>An outcome of dementia requires at least two diagnosis codes international classification of diseases, ninth revision, clinical modification (ICD-9-CM) or international classification of diseases, tenth revision, clinical modification (ICD-10-CM) for dementia within 365 days of each other.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Newly Diagnosed Alzheimer's Disease (AD) Cases</measure>
    <time_frame>365 days</time_frame>
    <description>An outcome of AD requires at least two diagnosis codes (ICD-9-CM or ICD-10-CM) for AD within 365 days of each other.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">34647</enrollment>
  <condition>Dementia</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Participants Initiating Therapy with Methotrexate or Anti-TNF</arm_group_label>
    <description>Data will be collected for participants initiating therapy with either methotrexate or an anti-tumor necrosis factor (TNF) from united states (US) claims databases: optum de-identified clinformatics data mart database and IBM marketscan medicare supplemental database (MDCR). Data collection period: 01-Jan-2000 through 31-Jul2019.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.</description>
    <arm_group_label>Participants Initiating Therapy with Methotrexate or Anti-TNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-TNF</intervention_name>
    <description>No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.</description>
    <arm_group_label>Participants Initiating Therapy with Methotrexate or Anti-TNF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population consists of participants who are new user of Anti-TNF therapy diagnosed&#xD;
        with dementia and alzheimer's disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least one claim for methotrexate or anti-TNF therapy during the study period. First&#xD;
             medication received is the index medication, and date of first receipt is the index&#xD;
             date&#xD;
&#xD;
          -  365 days of continuous pre-index observation immediately prior to the index date&#xD;
&#xD;
          -  Participants have at least two occurrences of a diagnosis of rheumatoid arthritis&#xD;
             within 365 days before and including the index date&#xD;
&#xD;
          -  No prior use of methotrexate or an anti- tumor necrosis factor (TNF) therapy at any&#xD;
             time prior to the index date&#xD;
&#xD;
          -  Cohort follow-up persists until end of continuous observation or filling the&#xD;
             comparator drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Janssen R&amp;D</name>
      <address>
        <city>Titusville</city>
        <state>New Jersey</state>
        <zip>08560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

